Regeneron Pharmaceuticals Inc. has published the transcript of its fourth-quarter 2025 earnings conference call, held on January 30, 2026. The event featured key members of Regeneron’s management team, including the President and Chief Executive Officer, the President and Chief Scientific Officer, the Executive Vice President of Commercial, and the Chief Financial Officer. During the call, executives discussed the company’s financial performance, ongoing development programs, and anticipated milestones. The management team provided updates on product pipelines, regulatory matters, and collaborations, while also addressing risks and uncertainties that could impact future performance. “Remarks made on today’s call may include forward-looking statements about Regeneron. Such statements may include but are not limited to those related to Regeneron and its products and business, financial forecast and guidance, development programs, and related anticipated milestones,” said the Senior Vice President of Investor Relations. The management also reminded listeners that both GAAP and non-GAAP financial measures were discussed and that reconciliations are available in the company’s quarterly results press release and corporate presentation. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.